Worldwide Clinical Trials

JULY 8, 2024

With radiopharmaceuticals emerging as a diagnostic and therapeutic (theranostics) procedure, many are in the clinical development pipeline and are expected to play a crucial role in the future of healthcare. Pregnancy : Radiation exposure during pregnancy can potentially harm the developing fetus.

Hormones 130

Hormones Regulation Clinical Trials Clinical Trials 130

Pharmaceutical Technology

JULY 25, 2022

AstraZeneca and Daiichi Sankyo have received Priority Review for their supplemental Biologics License Application (sBLA) from the US Food and Drug Administration (FDA) of antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), to treat unresectable or metastatic HER2-low breast cancer in adults.

HR 130

HR Hormones Clinical Trials Clinical Trials 130

Pharmaceutical Technology

FEBRUARY 14, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin 1, which are now well established in the industry.

Antibody 130

Antibody Hormones DNA Licensing 130

pharmaphorum

DECEMBER 9, 2022

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu is already making waves in breast cancer, and clinical results presented at the San Antonio Breast Cancer Symposium (SABCS) suggest they may see success with a second. The post SABCS: New ADC from AZ and Daiichi shows promise in breast cancer appeared first on.

HR 98

HR Antibody Hormones Drugs 98

pharmaphorum

SEPTEMBER 14, 2020

Merck & Co has signed a multi-billion cancer drug development deal, which will see it investing $1 billion in partner Seattle Genetics. US-based Merck, known as MSD outside North America, will globally develop and market Seattle’s investigational antibody-drug conjugate (ladiratuzumab vedotin).

Genetics 52

Genetics Development Drugs Protein 52

pharmaphorum

NOVEMBER 6, 2020

Its lead candidate in clinical development is VLS-101, an antibody-drug conjugate (ADC) targeting ROR1 that is being tested in a phase 1 and a phase 2 clinical trial for patients with blood cancer and solid tumours, respectively. The transaction is expected to close at the end of 2020.

Antibody 85

Antibody Hormones Trials Clinical Trials 85

pharmaphorum

DECEMBER 12, 2022

Along with data from its antibody-drug conjugates and oral selective oestrogen receptor degrader (SERD) camizestrant reported earlier, AZ presented results of the CAPItello trial of AKT inhibitor capivasertib in combination with injectable SERD Faslodex (fulvestrant) in hormone receptor positive, HER2-negative advanced breast cancer.

HR 105

HR Hormones Trials Drugs 105

XTalks

NOVEMBER 26, 2020

In addition to innovative new antibody drugs and mRNA vaccines, researchers have found that the sleep-regulating hormone melatonin may also offer protection against COVID-19. Lerner researchers developed a novel artificial intelligence platform to identify potential drugs for COVID-19, finding melatonin to be a promising candidate.

Research 98

Research Hormones Protein Regulation 98

pharmaphorum

JULY 14, 2022

In a statement , the health technology assessment (HTA) organisation said that the two drugs were backed after an agreement with the two developers on pricing that will make them an option for around 3,450 NHS patients.

Drugs 104

Drugs Hormones Genomics Genome 104

Pharmaceutical Technology

SEPTEMBER 13, 2022

Hormone receptor-positive/human epidermal growth factor negative (HR+/HER2-) breast cancer accounts for approximately 70% of all breast cancers, with close to 40,000 new cases diagnosed each year worldwide. Trop-2 is highly expressed across multiple cancer types, with expression detected in more than 90% of breast cancers.

HR 162

HR Marketing Hormones FDA Approval 162

Pharmaceutical Technology

FEBRUARY 18, 2023

The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The drug candidate is administered orally.

Hormones 100

Hormones Development Production Clinical Trials 100

pharmaphorum

JULY 8, 2021

million grant will be used to develop a new class of small-molecule inhibitors of M pro , a protease enzyme essential for the replication of the SARS-CoV-2 virus. The latest Gates Foundation grant comes on top of earlier awards for tuberculosis, malaria and non-hormonal contraceptives which were announced earlier this year.

Drugs 111

Drugs Hormones Medicine Antibody 111

XTalks

DECEMBER 5, 2024

Amgens randomized, double-blind, placebo-controlled Phase II study enrolled 592 adults with obesity or overweight conditions, defined by a body mass index (BMI) of 30 or 27, respectively, with at least one obesity-related comorbidity.

Trials 104

Trials Drugs Clinical Trials Clinical Trials 104

pharmaphorum

FEBRUARY 21, 2022

” The antibody-drug conjugate is already approved as a third-line therapy for HER2-positive metastatic breast cancer and a second-line therapy for HER2-positive metastatic gastric cancer, and recent data from the DESTINY-Breast03 study looks set to expand its use into second-line treatment in breast cancer. AZ paid a hefty $1.4

Trials 132

Trials Sales Hormones Drugs 132

XTalks

DECEMBER 5, 2024

Amgen’s randomized, double-blind, placebo-controlled Phase II study enrolled 592 adults with obesity or overweight conditions, defined by a body mass index (BMI) of ≥30 or ≥27, respectively, with at least one obesity-related comorbidity. “We

Trials 96

Trials Drugs Clinical Trials Clinical Trials 96

Find Me Cure

OCTOBER 13, 2019

If you follow our blog you know that we at FindMeCure take updating our readership on treatments in development very seriously. CDK4/6 inhibitors are used alongside hormone therapy. There are antibody drugs targetting those cells that are already FDA approved and there are antibody drugs still in trials.

Development 52

Development DNA Clinical Trials Clinical Trials 52

XTalks

NOVEMBER 5, 2024

SEP-786, an oral parathyroid hormone 1 receptor (PTH1R) agonist, aims to restore essential mineral balance. Septerna’s thyroid-stimulating hormone receptor (TSHR) modulators offer a potentially disease-modifying oral treatment. Phase I trials are underway, with data expected in mid-2025. million patients in the US.

Drugs 59

Drugs Hormones Protein Antibody 59

XTalks

MARCH 29, 2021

Grantz, of the Division of Intramural Population Health Research at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development. Related: Maternal Antibodies: How Allergies Can be Passed from Mothers to Children. Katherine L.

Genotype 98

Genotype Allergies Hormones Research 98

Delveinsight

AUGUST 2, 2020

Cachexia is observed as a result of underlying diseases, including cancer, AIDS, tuberculosis, chronic heart failure, hormonal deficiency, and others. NGM120 is a first-in-class antagonistic antibody, which binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15).

Marketing 94

Marketing Pharma Companies Development Hormones 94

XTalks

MARCH 22, 2021

And as big pharma works on developing and growing their oncology portfolios, the rising trend of such mergers and acquisitions won’t be slowing down any time soon. Resolution has been a leader in the development of NGS-based companion diagnostics (CDx) test development and registration services for precision oncology.

Life Science 110

Life Science Development Marketing Gene Expression 110

XTalks

FEBRUARY 5, 2024

This article serves as a resource for healthcare professionals, life sciences researchers and industry enthusiasts seeking to stay informed of the latest developments and success stories in oncology therapeutics. Darzalex (Daratumumab) Darzalex 2022 Sales: $7.977 billion Company/Developer: Janssen Biotech, Inc.,

FDA Approval 101

FDA Approval Drugs Sales Development 101

XTalks

FEBRUARY 7, 2023

Current treatments for HR+ breast cancer patients include hormonal therapies, chemotherapies for those that do not respond to hormonal therapy alone and targeted therapies, either stand-alone or in combination with hormonal therapies. Trodelvy is a Targeted Therapy Trodelvy is a Trop -2 directed antibody-drug conjugate therapy.

HR 52

HR Hormones FDA Approval Antibody 52

pharmaphorum

DECEMBER 23, 2020

Originally developed to treat late-stage EGFR-mutated disease, the ADAURA study tested Tagrisso as an adjuvant treatment in patients with early disease following surgery. A molecule codenamed DNL151, currently in phase 1 development, has been selected to progress into late-stage clinical studies that are expected to begin in 2021.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

Roots Analysis

MARCH 21, 2022

Biologics have emerged as a direct consequence of the rapid development that has taken place in the field of life sciences, particularly in cell and molecular biology, over the past few decades. There are a variety of biologically derived therapeutics that are presently available / being developed.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Antibody Drugs 52

XTalks

NOVEMBER 20, 2023

AstraZeneca has won its first-in-class approval for its AKT inhibitor Truqap (capivasertib) in combination with Faslodex (fulvestrant) for treating patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.

HR 98

HR FDA Approval Gene Trials 98

pharmaphorum

JULY 13, 2022

Merck – known as MSD outside the US and Canada – is paying $290 million upfront for global co-development and co-marketing rights to ODM-208, a steroid synthesis inhibitor, as well as follow-up compounds in the same class. Further financial terms have not been disclosed.

Licensing 52

Licensing Licensing Hormones Production 52

The Pharma Data

JUNE 26, 2021

Chemist Han Xiao at Rice and biologist Xiang Zhang at Baylor and their labs have developed an antibody conjugate called BonTarg that delivers drugs to bone tumors and inhibits metastasis. Harnessing the power of antibodies to fight bone metastasis. “We feel our strategy is a real game changer.”

Drugs 52

Drugs Antibody Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 7, 2021

Frank Nestle, Sanofi’s chief scientific officer and Global Head of Research, and Dietmar Berger, Sanofi’s chief medical officer and Global Head of Development, provided an overview of the company’s clinical activities and highlighted some of the assets that will be key revenue drives for the company. That’s a significant goal.

Protein 52

Protein Antibody Genetics Gene Therapy 52

XTalks

SEPTEMBER 17, 2020

While the table lists acceptable surrogate endpoints for trials of more common conditions, such as asthma, type 2 diabetes and various cancer types, the document also provides key information to developers of certain rare disease therapies. The tumor secretes adrenocorticotropic hormone (ACTH), which stimulates cortisol production.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Roots Analysis

OCTOBER 24, 2023

This has led to their widespread production and extensive use in the treatment of various indications including hormonal imbalances, oncological disorders and respiratory disorders. Different Types of HPAPIs The new generation of APIs being developed are highly complex in nature, including peptides, HPAPIs, oligonucleotides and sterile APIs.

Manufacturing 40

Manufacturing Hormones Contamination Containment 40

The Pharma Data

FEBRUARY 21, 2022

Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo. 4 Currently, chemotherapy remains the only treatment option both for patients with HR-positive tumours following progression on endocrine (hormone) therapy, and for those who are HR-negative.5.

HR 52

HR Trials Hormones Antibody 52

XTalks

NOVEMBER 2, 2020

This includes compromising the functioning of the adrenal glands, which can potentially lead to adrenal insufficiency, resulting in inadequate production of steroid hormones. Fasenra is currently under development for other eosinophilic diseases and chronic obstructive pulmonary disease. a wholly-owned subsidiary of Kyowa Kirin Co.,

Trials 94

Trials FDA Approval Drugs Hormones 94

pharmaphorum

AUGUST 16, 2022

The deal gives it worldwide ownership of Trodelvy (sacituzumab govitecan), a first-in-class TROP2 antibody-drug conjugate drug it acquired as part of its $21 billion takeover of Immunomedics in 2020.

Licensing 52

Licensing Licensing Hormones Drugs 52

The Pharma Data

SEPTEMBER 28, 2021

Merck is rapidly advancing a broad portfolio in gynecologic and breast cancers through an in depth clinical development program for KEYTRUDA and a number of other other investigational and approved medicines across these areas. About Triple-Negative carcinoma. Merck has the industry’s largest immuno-oncology clinical research program.

Hormones 52

Hormones Medicine Clinical Research Research 52

pharmaphorum

JANUARY 10, 2023

It was approved by the FDA as Sotyktu last September; 5) Foscarbidopa/foslevodopa ( ABBV-951 ): Developed by AbbVie, the drug is a reformulation of a standard Parkinson’s treatment (carbidopa/levodopa) delivered by subcutaneous pump for hard-to-treat patients with advanced disease, and is in the latter stages of FDA review.

Drugs 52

Drugs Gene Therapy Antibody Insulin 52

pharmaphorum

OCTOBER 12, 2022

Gilead Sciences will hear back from the FDA in February next year about its marketing application for Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer, billed by the drugmaker as a key new indication for the drug.

HR 52

HR Sales Antibody Hormones 52